Peanut Allergy Epidemiology Forecast

DelveInsight’s ‘Peanut Allergy– Epidemiology Forecast – 2030’ report delivers an in-depth understanding of the historical and forecasted epidemiology of Peanut Allergy in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Peanut Allergy: Disease Understanding

Peanut Allergy Overview

According to the US Food and Drug Administration (FDA) Peanut allergy is a condition in which the body’s immune system does not recognize peanut protein and mistakenly identifies even tiny amounts of peanut as harmful. Allergic reactions to peanuts are unpredictable in occurrence and how they present, with some individuals experiencing severe reactions from even trace amounts.


The allergy results from an IgE-mediated immediate hypersensitivity reaction to the consumption of peanuts (the seeds of Arachis hypogaea). Peanut allergens are designated Ara by the World Health Organization (WHO). Peanut allergy is the most important food allergy in the US, affecting more than a million people. Reactions range from mild (rashes) to life-threatening (closure of the airway, cardiac dysrhythmias, and coma). About 50 people die of peanut allergy in the US each year. A peanut allergy occurs when a person’s immune system does not recognize peanut protein and mistakenly overreacts. Both genetic and environmental factors appear to be involved.


The Centers for Disease Control and Prevention (CDC) reports that children with food allergies are more expected to have asthma or other allergic conditions. Nearly 90% of food allergies are caused by these common foods: tree nuts (almonds, walnuts, pecans, cashews, pistachios, etc.), peanuts, milk, eggs, fish, crustacean shellfish, wheat, and soy.


Peanut allergy symptoms may be mild or may manifest as a severe anaphylactic reaction like urticaria – a red, blotchy, and intensely itchy skin rash commonly referred to as hives. In addition, symptoms include swelling (angioedema) of the face, eyelids, lips, tongue, roof of the mouth, or throat; abdominal cramps, diarrhea, nausea, vomiting; and runny and itchy nose.


Anaphylaxis is the most common reaction in peanut allergy patients; it describes a severe and life-threatening allergic reaction. An anaphylactic response is characterized by a swelling of the larynx (voice box) that disrupts the passage of air into the lungs, leading to severe shortness of breath. The swollen larynx also makes it difficult to speak and swallow. In addition, dilated blood vessels may cause a sharp fall of blood pressure, with the skin turning cool and clammy and the sufferer feeling dizzy or even losing consciousness. An intense feeling of dread and anxiety may be accompanied by a weak but rapid pulse.


Concerning the mechanism of peanut allergy, at first exposure, the immune system reacts to proteins in the peanuts by producing the antibody immunoglobulin E (IgE), which binds to receptors present on mast cells and basophils. Subsequent exposure to peanuts leads to an inflammatory response governed by these cells, as the peanut protein causes the IgE/receptor complexes to cross-link and activate the release of the inflammatory mediators (e.g., histamine) inside them. Histamine and other inflammatory mediators then trigger the symptoms of an allergic reaction.


Diagnosis of peanut allergy involves a detailed evaluation of a patient’s diet history and the severity and duration of their symptoms on exposure to peanuts. Next, a skin test for the allergy may be performed or a blood sample taken to check for IgE. A positive challenge test may be performed in rare cases, where the peanut protein is administered to the patient to examine their allergic reaction.


The US FDA has approved Palforzia (Peanut [Arachis hypogaea] Allergen Powder-dnfp) to mitigate allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanuts.

Peanut Allergy: Epidemiology

The Peanut Allergy epidemiology division provides insights into the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool, trends, and assumptions.


Key Findings

The disease epidemiology covered in the report provides historical and forecasted Peanut Allergy epidemiology segmented as the diagnosed prevalence of peanut allergy, gender-specific cases of peanut allergy, age-specific cases of peanut allergy, and severity-specific cases of peanut allergy. The report includes the prevalent scenario of Peanut Allergy in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country-wise Peanut Allergy Epidemiology

The epidemiology segment also provides the Peanut Allergy epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.


The total prevalent population of Peanut Allergy in the 7MM countries was estimated to be 10,578,543 cases in 2020.


As per the estimates, United States had the largest Prevalence of Peanut Allergy in 2020. Among the EU5 countries, Germany had the largest prevalent population of Peanut Allergy with 1,017,263 cases, followed by France in 2020. On the other hand, Spain had the lowest prevalent population of 638,493 cases in 2020.

Scope of the Report

  • Peanut Allergy report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
  • Peanut Allergy epidemiology report and model provides an overview of the risk factors and global Peanut Allergy trends in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report provides insight into the historical and forecasted patient pool of Peanut Allergy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps recognize the growth opportunities in the 7MM concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of Peanut Allergy.
  • The report provides the segmentation of the Peanut Allergy epidemiology by the diagnosed prevalence of Peanut Allergy in the 7MM.
  • The report provides the segmentation of the Peanut Allergy epidemiology by gender-specific cases of Peanut Allergy in the 7MM.
  • The report provides the segmentation of the Peanut Allergy epidemiology by age-specific cases of Peanut Allergy in the 7MM.
  • The report provides the segmentation of the Peanut Allergy epidemiology by severity-specific cases of Peanut Allergy in the 7MM.

Report Highlights

  • 10-year Forecast of Peanut Allergy epidemiology
  • 7MM Coverage
  • Diagnosed Prevalent Cases of Peanut Allergy in the 7MM
  • Gender-specific cases of Peanut Allergy in the 7MM
  • Age-specific cases of Peanut Allergy in the 7MM
  • Severity-specific cases of Peanut Allergy in the 7MM

KOL Views

We interview KOLs and obtain SME’s opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM for the patient population pertaining to Peanut Allergy?
  • What are the key findings pertaining to the Peanut Allergy epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2018–2030)?
  • What would be the total number of patients with Peanut Allergy across the 7MM during the forecast period (2018–2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2018–2030)?
  • At what CAGR the patient population is expected to grow by 7MM during the forecast period (2018–2030)?
  • What are the disease risk, burdens, and unmet needs of Peanut Allergy?
  • What are the currently available treatments for Peanut Allergy?

Reasons to buy

Peanut Allergy Epidemiology report will allow the user to:

  • Develop business strategies by understanding the trends shaping and driving the global Peanut Allergy market.
  • Quantify patient populations in the global Peanut Allergy market to improve product design, pricing, and launch plans.
  • Understand the magnitude of the Peanut Allergy population by its diagnosed prevalent cases in the 7MM.
  • Understand the magnitude of the Peanut Allergy by its gender-specific cases in the 7MM.
  • Understand the magnitude of the Peanut Allergy by its age-specific cases in the 7MM.
  • Understand the magnitude of the Peanut Allergy by its severity-specific cases in the 7MM.
  • The Peanut Allergy epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
  • The Peanut Allergy Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insight

2. Report Introduction

3. Peanut Allergy Market Overview at a Glance

3.1. Patient Share (%) Distribution of Peanut Allergy in 2018

3.2. Patient Share (%) Distribution of Peanut Allergy in 2030

4. Executive Summary of Peanut Allergy 17

5. Disease Background and Overview

5.1. Introduction

5.2. Clinical Manifestations

5.3. Mechanisms of Peanut Allergy

5.4. Risk Factors

5.5. Classification of Peanut allergy

5.6. Diagnosis

5.7. Treatment and Management

5.7.1. Treatment Guidelines

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total Diagnosed Prevalence of Peanut Allergy

6.3. Epidemiology of Peanut Allergy

6.4. The United States

6.4.1. Diagnosed Prevalence of Peanut Allergy in the United States

6.4.2. Gender-specific cases of Peanut Allergy in the United States

6.4.3. Age-specific cases of Peanut Allergy in the United States

6.4.4. Severity-specific cases of Peanut Allergy in the United States

6.5. EU5

6.5.1. Germany

6.5.1.1. Diagnosed Prevalence of Peanut Allergy in Germany

6.5.1.2. Gender-specific cases of Peanut Allergy in Germany

6.5.1.3. Age-specific cases of Peanut Allergy in Germany

6.5.1.4. Severity-specific cases of Peanut Allergy in Germany

6.5.2. France

6.5.2.1. Diagnosed Prevalence of Peanut Allergy in France

6.5.2.2. Gender-specific cases of Peanut Allergy in France

6.5.2.3. Age-specific cases of Peanut Allergy in France

6.5.2.4. Severity-specific cases of Peanut Allergy in France

6.5.3. Italy

6.5.3.1. Diagnosed Prevalence of Peanut Allergy in Italy

6.5.3.2. Gender-specific cases of Peanut Allergy in Italy

6.5.3.3. Age-specific cases of Peanut Allergy in Italy

6.5.3.4. Severity-specific cases of Peanut Allergy in Italy

6.5.4. Spain

6.5.4.1. Diagnosed Prevalence of Peanut Allergy in Spain

6.5.4.2. Gender-specific cases of Peanut Allergy in Spain

6.5.4.3. Age-specific cases of Peanut Allergy in Spain

6.5.4.4. Severity-specific cases of Peanut Allergy in Spain

6.5.5. The United Kingdom

6.5.5.1. Diagnosed Prevalence of Peanut Allergy in the UK

6.5.5.2. Gender-specific cases of Peanut Allergy in the UK

6.5.5.3. Age-specific cases of Peanut Allergy in the UK

6.5.5.4. Severity-specific cases of Peanut Allergy in the UK

6.6. Japan

6.6.1. Diagnosed Prevalence of Peanut Allergy in Japan

6.6.2. Gender-specific cases of Peanut Allergy in Japan

6.6.3. Age-specific cases of Peanut Allergy in Japan

6.6.4. Severity-specific cases of Peanut Allergy in Japan

7. KOL Views

8. Appendix

8.1. Bibliography

8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

List of Table

Table 1: Summary of Peanut Allergy, Epidemiology, and Key Events (2018–2030)

Table 2: Biochemical Classification of Peanut Allergy

Table 3: Summary of Addendum Guidelines 1, 2, and 3

Table 4: Considerations for implementing recommendations made in EACCI guidelines

Table 5: Diagnosed Prevalence of Peanut Allergy in 000’s in the 7MM (2018–2030)

Table 6: Diagnosed Prevalence of Peanut Allergy in 000’s in the United States (2018–2030)

Table 7: Gender-specific cases of Peanut Allergy in 000’s in the United States (2018–2030)

Table 8: Age-specific cases of Peanut Allergy in 000’s in the United States (2018–2030)

Table 9: Severity-specific cases of Peanut Allergy in 000’s in the United States (2018–2030)

Table 10: Diagnosed Prevalence of Peanut Allergy in 000’s in Germany (2018–2030)

Table 11: Gender-specific cases of Peanut Allergy in Germany (2018–2030)

Table 12: Age-specific cases of Peanut Allergy in Germany (2018–2030)

Table 13: Severity-specific cases of Peanut Allergy in Germany (2018–2030)

Table 14: Diagnosed Prevalence of Peanut Allergy in France (2018–2030)

Table 15: Gender-specific cases of Peanut Allergy in France (2018–2030)

Table 16: Age-specific cases of Peanut Allergy in France (2018–2030)

Table 17: Severity-specific cases of Peanut Allergy in France (2018–2030)

Table 18: Diagnosed Prevalence of Peanut Allergy in Italy (2018–2030)

Table 19: Gender-specific cases of Peanut Allergy in Italy (2018–2030)

Table 20: Age-specific cases of Peanut Allergy in Italy (2018–2030)

Table 21: Severity-specific cases of Peanut Allergy in Italy (2018–2030)

Table 22: Diagnosed Prevalence of Peanut Allergy in Spain (2018–2030)

Table 23: Gender-specific cases of Peanut Allergy in Spain (2018–2030)

Table 24: Age-specific cases of Peanut Allergy in Spain (2018–2030)

Table 25: Severity-specific cases of Peanut Allergy in Spain (2018–2030)

Table 26: Diagnosed Prevalence of Peanut Allergy in the United Kingdom (2018–2030)

Table 27: Gender-specific cases of Peanut Allergy in the United Kingdom (2018–2030)

Table 28: Age-specific cases of Peanut Allergy in the United Kingdom (2018–2030)

Table 29: Severity-specific cases of Peanut Allergy in the United Kingdom (2018–2030)

Table 30: Diagnosed Prevalence of Peanut Allergy in Japan (2018–2030)

Table 31: Gender-specific cases of Peanut Allergy in Japan (2018–2030)

Table 32: Age-specific cases of Peanut Allergy in Japan (2018–2030)

Table 33: Severity-specific cases of Peanut Allergy in Japan (2018–2030)

List of Figures

Figure 1: Signs and Symptoms of Peanut Allergy

Figure 2: Mechanism of Action of Peanut Allergy

Figure 3: Risk Factors of Peanut allergy

Figure 4: Diagnostic Methods for Peanut Allergy

Figure 5: Algorithm for the Diagnosis of Peanut Allergy

Figure 6: Management of Peanut Allergy

Figure 7: Japanese Pediatric Guideline for Food Allergy (JPGFA)

Figure 8: Total Diagnosed Prevalent Population of Peanut Allergy in 7MM (2018–2030)

Figure 9: Diagnosed Prevalence of Peanut Allergy in the United States (2018–2030)

Figure 10: Gender-specific cases of Peanut Allergy in the United States (2018–2030)

Figure 11: Age-specific cases of Peanut Allergy in the United States (2018–2030)

Figure 12: Severity-specific cases of Peanut Allergy in the United States (2018–2030)

Figure 13: Diagnosed Prevalence of Peanut Allergy in Germany (2018–2030)

Figure 14: Gender-specific cases of Peanut Allergy in Germany (2018–2030)

Figure 15: Age-specific cases of Peanut Allergy in Germany (2018–2030)

Figure 16: Severity-specific cases of Peanut Allergy in Germany (2018–2030)

Figure 17: Diagnosed Prevalence of Peanut Allergy in France (2018–2030)

Figure 18: Gender-specific cases of Peanut Allergy in France (2018–2030)

Figure 19: Age-specific cases of Peanut Allergy in France (2018–2030)

Figure 20: Severity-specific cases of Peanut Allergy in France (2018–2030)

Figure 21: Diagnosed Prevalence of Peanut Allergy in Italy (2018–2030)

Figure 22: Gender-specific cases of Peanut Allergy in Italy (2018–2030)

Figure 23: Age-specific cases of Peanut Allergy in Italy (2018–2030)

Figure 24: Severity-specific cases of Peanut Allergy in Italy (2018–2030)

Figure 25: Diagnosed Prevalence of Peanut Allergy in Spain (2018–2030)

Figure 26: Gender-specific cases of Peanut Allergy in Spain (2018–2030)

Figure 27: Age-specific cases of Peanut Allergy in Spain (2018–2030)

Figure 28: Severity-specific cases of Peanut Allergy in Spain (2018–2030)

Figure 29: Diagnosed Prevalence of Peanut Allergy in the United Kingdom (2018–2030)

Figure 30: Gender-specific cases of Peanut Allergy in the United Kingdom (2018–2030)

Figure 31: Age-specific cases of Peanut Allergy in the United Kingdom (2018–2030)

Figure 32: Severity-specific cases of Peanut Allergy in the United Kingdom (2018–2030)

Figure 33: Diagnosed Prevalence of Peanut Allergy in Japan (2018–2030)

Figure 34: Gender-specific cases of Peanut Allergy in Japan (2018–2030)

Figure 35: Age-specific cases of Peanut Allergy in Japan (2018–2030)

Figure 36: Severity-specific cases of Peanut Allergy in Japan (2018–2030)

  • Tags:
  • Peanut Allergy Epidemiology
  • Peanut Allergy
  • Peanut Allergy Pipeline
  • Peanut Allergy Companies
  • Peanut Allergy prevalent populatio...
  • Peanut Allergy incident population
  • Peanut Allergy patients diagnosed
  • Peanut Allergy treatment algorithm...

Forward to Friend

Need A Quote